Karl-Erik Andersson (academic)

Last updated
  1. "Lund University–Karl-Erik Andersson".
  2. 1 2 "Google Scholar–Karl-Erik Andersson".
  3. 1 2 "22nd Congress of the European Society for Sexual Medicine" (PDF).
  4. 1 2 "SUFU–Lifetime Achievement Award".
  5. 1 2 "ICS Members–Karl-Erik Andersson".
  6. 1 2 "Medals and Awards–2008".
  7. 1 2 "EAU Opening Ceremony".
  8. 1 2 "Royal Physiographic Society in Lund–Current Fellows".
  9. "ICS Hall of Fame–Karl-Erik Andersson".
  10. "Wake Forest University School of Medicine–Alumni News and Notes".
  11. Pfeifer, A.; Klatt, P.; Massberg, S.; Ny, L.; Sausbier, M.; Hirneiss, C.; Wang, G. X.; Korth, M.; Aszódi, A.; Andersson, K. E.; Krombach, F.; Mayerhofer, A.; Ruth, P.; Fässler, R.; Hofmann, F. (1998). "Defective smooth muscle regulation in cGMP kinase I-deficient mice". The EMBO Journal. pp. 3045–3051. doi:10.1093/emboj/17.11.3045. PMC   1170644 . PMID   9606187.
  12. "Pharmacology of Penile Erection".
  13. Michel, Martin C.; Cardozo, Linda; Chermansky, Christopher J.; Cruz, Francisco; Igawa, Yasuhiko; Lee, Kyu-Sung; Sahai, Arun; Wein, Alan J.; Andersson, Karl-Erik (2023). "Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders". Pharmacological Reviews. 75 (4): 554–674. doi:10.1124/pharmrev.121.000523. PMID   36918261.
  14. Andersson, Karl-Erik; Arner, Anders (2004). "Urinary Bladder Contraction and Relaxation: Physiology and Pathophysiology". Physiological Reviews. 84 (3): 935–986. doi:10.1152/physrev.00038.2003. PMID   15269341.
  15. Kanai, A.J.; Andersson, K.-E.; Fry, C.H.; Yoshimura, N. (2023). "Targeting neurotrophin and nitric oxide signaling to promote recovery and ameliorate neurogenic bladder dysfunction following spinal cord injury – Mechanistic concepts and clinical implications". Continence. 6. doi:10.1016/j.cont.2023.100703. PMC   10310066 . PMID   37389025.
  16. Andersson, Karl-Erik (2024). "Promising therapeutic targets for the treatment of urine storage dysfunction: what's the status?". Expert Opinion on Therapeutic Targets. 28 (4): 251–258. doi: 10.1080/14728222.2024.2344698 . PMID   38629152.
  17. Kanai, A.J.; Andersson, K.-E.; Birder, L.A.; Fry, C.H. (2023). "Soluble Guanylate Cyclase Activators to Treat Benign Prostatic Hyperplasia and associated LUTS". Continence. 6. doi:10.1016/j.cont.2023.100699. PMC   10310070 . PMID   37389026.
Karl-Erik Andersson
Born
Nationality Swedish
Occupation(s)Pharmacologist and academic
Academic background
EducationMD
PhD
Alma mater Lund University